{"id":53959,"date":"2026-01-13T21:22:10","date_gmt":"2026-01-13T13:22:10","guid":{"rendered":"https:\/\/flcube.com\/?p=53959"},"modified":"2026-01-13T21:22:11","modified_gmt":"2026-01-13T13:22:11","slug":"hengruis-hrs-7535-glp-1r-agonist-cleared-for-hypertension-with-obesity-study-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53959","title":{"rendered":"Hengrui\u2019s HRS-7535 GLP-1R Agonist Cleared for Hypertension with Obesity Study in China"},"content":{"rendered":"\n<p><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA:\u202f600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG:\u202f1276<\/a>) announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has authorized <strong>HRS-7535<\/strong>, a novel <strong>oral small\u2011molecule GLP\u20111 receptor (GLP\u20111R) agonist<\/strong>, to enter clinical studies for <strong>hypertension comorbid with overweight or obesity<\/strong>, positioning Hengrui at the forefront of next\u2011generation metabolic disease therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Jiangsu Hengrui Pharmaceuticals (600276.SH, 1276.HK)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>HRS-7535 (oral small\u2011molecule GLP\u20111R agonist)<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>Clinical Trial Authorization (CTA)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Hypertension with overweight\/obesity comorbidity<\/td><\/tr><tr><td><strong>Authorization Date<\/strong><\/td><td>12\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Next Milestone<\/strong><\/td><td>Phase\u202fI\/II study initiation expected Q2\u202f2026<\/td><\/tr><tr><td><strong>Additional Indications<\/strong><\/td><td>Type\u202f2 diabetes and weight loss (also in development)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Oral small\u2011molecule glucagon\u2011like peptide\u20111 receptor (GLP\u20111R) agonist<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Activates human GLP\u20111R to:<\/li>\n\n\n\n<li><strong>Promote pancreatic insulin secretion<\/strong> and reduce glucagon release<\/li>\n\n\n\n<li><strong>Inhibit gastric emptying<\/strong> and enhance satiety via central nervous system effects<\/li>\n\n\n\n<li><strong>Suppress appetite<\/strong> and directly reduce energy intake<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> <strong>First oral small\u2011molecule GLP\u20111R agonist<\/strong> entering clinical trials globally; offers potential manufacturing cost advantages and improved stability compared to peptide\u2011based injectables and oral tablets (e.g., Rybelsus)<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Pre\u2011clinical efficacy demonstrated in rodent and non\u2011human primate models; IND\u2011enabling toxicology completed<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-hypertension-with-obesity\">Market Opportunity: Hypertension with Obesity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>Hypertension Prevalence<\/strong><\/td><td>330\u202fmillion<\/td><td>1.28\u202fbillion<\/td><\/tr><tr><td><strong>With Overweight\/Obesity Comorbidity<\/strong><\/td><td>115\u202fmillion<\/td><td>450\u202fmillion<\/td><\/tr><tr><td><strong>Currently Treated with GLP\u20111<\/strong><\/td><td>&lt;2\u202f%<\/td><td>&lt;3\u202f%<\/td><\/tr><tr><td><strong>Addressable Market (2030E)<\/strong><\/td><td>18\u202fmillion patients<\/td><td>72\u202fmillion patients<\/td><\/tr><tr><td><strong>Annual Treatment Cost (China)<\/strong><\/td><td>\u00a58,000\u201112,000<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need:<\/strong> Current antihypertensives (ACE inhibitors, ARBs) do not address obesity\u2011driven pathophysiology; GLP\u20111R agonists offer <strong>dual metabolic and cardiovascular benefits<\/strong><\/li>\n\n\n\n<li><strong>Clinical Rationale:<\/strong> Semaglutide (injectable) demonstrated <strong>5\u20117\u202fmmHg systolic BP reduction<\/strong> in obese patients; oral small molecule could replicate benefits with superior convenience<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape-oral-glp-1r-space\">Competitive Landscape: Oral GLP\u20111R Space<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Drug<\/th><th>Mechanism<\/th><th>Stage<\/th><th>Key Differentiator<\/th><\/tr><\/thead><tbody><tr><td><strong>Hengrui<\/strong><\/td><td><strong>HRS\u20117535<\/strong><\/td><td>Small molecule<\/td><td>Phase\u202fI ready<\/td><td>Oral non\u2011peptide; China\u2011first<\/td><\/tr><tr><td><strong>Rybelsus<\/strong><\/td><td>Semaglutide<\/td><td>Oral peptide<\/td><td>Marketed<\/td><td>First oral GLP\u20111, but peptide\u2011based<\/td><\/tr><tr><td><strong>Pfizer<\/strong><\/td><td>Danuglipron<\/td><td>Small molecule<\/td><td>Phase\u202fII<\/td><td>Discontinued GI tolerability issues<\/td><\/tr><tr><td><strong>Eli Lilly<\/strong><\/td><td>Orforglipron<\/td><td>Small molecule<\/td><td>Phase\u202fIII<\/td><td>Dual GIP\/GLP\u20111; 2027E launch<\/td><\/tr><tr><td><strong>Structure<\/strong><\/td><td><strong>None<\/strong><\/td><td>Small molecule<\/td><td>\u2013<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Strategic Moat:<\/strong> HRS\u20117535 is the <strong>first and only oral small\u2011molecule GLP\u20111R agonist<\/strong> in China\u2019s pipeline; potential for <strong>global first\u2011in\u2011class<\/strong> if Phase\u202fI data proves competitive<\/li>\n\n\n\n<li><strong>Timeline Advantage:<\/strong> 12\u201118\u2011month head start vs. multinational competitors in China; NMPA fast\u2011track eligibility for cardiometabolic diseases<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-timeline-amp-revenue-forecast\">Development Timeline &amp; Revenue Forecast<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Expected Date<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase\u202fI initiation<\/strong><\/td><td>Q2\u202f2026<\/td><\/tr><tr><td><strong>Phase\u202fI\/II data<\/strong><\/td><td>Q1\u202f2027<\/td><\/tr><tr><td><strong>Phase\u202fIII start<\/strong><\/td><td>Q4\u202f2027<\/td><\/tr><tr><td><strong>NDA submission<\/strong><\/td><td>Q2\u202f2029<\/td><\/tr><tr><td><strong>Potential launch<\/strong><\/td><td>Q4\u202f2030<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2030E<\/th><th>2031E<\/th><th>2032E<\/th><\/tr><\/thead><tbody><tr><td><strong>China Market Penetration<\/strong><\/td><td>0\u202f%<\/td><td>3\u202f%<\/td><td>8\u202f%<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>\u2013<\/td><td>3.5\u202fmillion<\/td><td>9.2\u202fmillion<\/td><\/tr><tr><td><strong>Annual Cost (\u00a5)<\/strong><\/td><td>\u2013<\/td><td>\u00a59,500<\/td><td>\u00a58,800<\/td><\/tr><tr><td><strong>Hengrui Revenue (\u00a5)<\/strong><\/td><td>\u2013<\/td><td>\u00a533\u202fbillion<\/td><td>\u00a581\u202fbillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Strategy:<\/strong> Hengrui plans <strong>US IND filing<\/strong> in <strong>2027<\/strong> leveraging China Phase\u202fI\/II data under FDA bridging study pathway<\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> Hengrui\u2019s Lianyungang facility (current capacity 2\u202fbillion tablets) will dedicate <strong>30\u202f% capacity<\/strong> to HRS\u20117535 upon approval<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and revenue forecasts for HRS\u20117535. Actual results may differ due to clinical trial outcomes, competitive dynamics, and evolving GLP\u20111 market access policies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/600276_20260113_UVLJ.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20260113_UVLJ.\"><\/object><a id=\"wp-block-file--media-4b66c198-6426-4322-a9f2-3c04a2cb4564\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/600276_20260113_UVLJ.pdf\">600276_20260113_UVLJ<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/600276_20260113_UVLJ.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-4b66c198-6426-4322-a9f2-3c04a2cb4564\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA:\u202f600276, HKG:\u202f1276) announced that China\u2019s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,2586,4228,4361,4551],"class_list":["post-53959","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-hot-targets","tag-sha-600276-2"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui\u2019s HRS-7535 GLP-1R Agonist Cleared for Hypertension with Obesity Study in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA:\u202f600276, HKG:\u202f1276) announced that China\u2019s National Medical Products Administration (NMPA) has authorized HRS-7535, a novel oral small\u2011molecule GLP\u20111 receptor (GLP\u20111R) agonist, to enter clinical studies for hypertension comorbid with overweight or obesity, positioning Hengrui at the forefront of next\u2011generation metabolic disease therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53959\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui\u2019s HRS-7535 GLP-1R Agonist Cleared for Hypertension with Obesity Study in China\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA:\u202f600276, HKG:\u202f1276) announced that China\u2019s National Medical Products Administration (NMPA) has authorized HRS-7535, a novel oral small\u2011molecule GLP\u20111 receptor (GLP\u20111R) agonist, to enter clinical studies for hypertension comorbid with overweight or obesity, positioning Hengrui at the forefront of next\u2011generation metabolic disease therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53959\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-13T13:22:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-13T13:22:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53959#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53959\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui\u2019s HRS-7535 GLP-1R Agonist Cleared for Hypertension with Obesity Study in China\",\"datePublished\":\"2026-01-13T13:22:10+00:00\",\"dateModified\":\"2026-01-13T13:22:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53959\"},\"wordCount\":524,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"Hot targets\",\"SHA:\u202f600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53959#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53959\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53959\",\"name\":\"Hengrui\u2019s HRS-7535 GLP-1R Agonist Cleared for Hypertension with Obesity Study in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-13T13:22:10+00:00\",\"dateModified\":\"2026-01-13T13:22:11+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA:\u202f600276, HKG:\u202f1276) announced that China\u2019s National Medical Products Administration (NMPA) has authorized HRS-7535, a novel oral small\u2011molecule GLP\u20111 receptor (GLP\u20111R) agonist, to enter clinical studies for hypertension comorbid with overweight or obesity, positioning Hengrui at the forefront of next\u2011generation metabolic disease therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53959#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53959\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53959#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui\u2019s HRS-7535 GLP-1R Agonist Cleared for Hypertension with Obesity Study in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui\u2019s HRS-7535 GLP-1R Agonist Cleared for Hypertension with Obesity Study in China - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA:\u202f600276, HKG:\u202f1276) announced that China\u2019s National Medical Products Administration (NMPA) has authorized HRS-7535, a novel oral small\u2011molecule GLP\u20111 receptor (GLP\u20111R) agonist, to enter clinical studies for hypertension comorbid with overweight or obesity, positioning Hengrui at the forefront of next\u2011generation metabolic disease therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53959","og_locale":"en_US","og_type":"article","og_title":"Hengrui\u2019s HRS-7535 GLP-1R Agonist Cleared for Hypertension with Obesity Study in China","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA:\u202f600276, HKG:\u202f1276) announced that China\u2019s National Medical Products Administration (NMPA) has authorized HRS-7535, a novel oral small\u2011molecule GLP\u20111 receptor (GLP\u20111R) agonist, to enter clinical studies for hypertension comorbid with overweight or obesity, positioning Hengrui at the forefront of next\u2011generation metabolic disease therapies.","og_url":"https:\/\/flcube.com\/?p=53959","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-13T13:22:10+00:00","article_modified_time":"2026-01-13T13:22:11+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53959#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53959"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui\u2019s HRS-7535 GLP-1R Agonist Cleared for Hypertension with Obesity Study in China","datePublished":"2026-01-13T13:22:10+00:00","dateModified":"2026-01-13T13:22:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53959"},"wordCount":524,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Hengrui Pharmaceuticals","HKG: 1276","Hot targets","SHA:\u202f600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53959#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53959","url":"https:\/\/flcube.com\/?p=53959","name":"Hengrui\u2019s HRS-7535 GLP-1R Agonist Cleared for Hypertension with Obesity Study in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-13T13:22:10+00:00","dateModified":"2026-01-13T13:22:11+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA:\u202f600276, HKG:\u202f1276) announced that China\u2019s National Medical Products Administration (NMPA) has authorized HRS-7535, a novel oral small\u2011molecule GLP\u20111 receptor (GLP\u20111R) agonist, to enter clinical studies for hypertension comorbid with overweight or obesity, positioning Hengrui at the forefront of next\u2011generation metabolic disease therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53959#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53959"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53959#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui\u2019s HRS-7535 GLP-1R Agonist Cleared for Hypertension with Obesity Study in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53959","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53959"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53959\/revisions"}],"predecessor-version":[{"id":53961,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53959\/revisions\/53961"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53959"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53959"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53959"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}